VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | Advances in targeted therapy for head & neck and thyroid cancers

Neil Gross • 12 Sep 2022
ESMO 2022
Head and Neck Cancer Thyroid Cancer

Neil Gross, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of neoadjuvant therapies for patients with head and neck cancer and the potential of surgical treatment for patients with thyroid cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Neil Gross

2:08
ORATOR: Surgical vs. non-surgical management of oropharyngeal cancer
Neil Gross • 12 Sep 2022
1:18
Neoadjuvant cemiplimab in patients with stage II-IV cutaneous squamous cell carcinoma
Neil Gross • 12 Sep 2022

Related Videos

3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
2:00
Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data
Ezra Cohen
3:10
The risks of radioactive iodine treatment in thyroid cancer
Remco Molenaar
0:58
Checkpoint inhibitors for head and neck cancer in the definitive setting?
Barbara Burtness
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals